HAART for children with treatment failure

HIV Therapy

Volumn 3, Issue 5, 2009, Pages 485-499

  Sohn, Annette H ^a   Ananworanich, Jintanat ^b,c  

^a TREAT Asia/amfAR The Foundation for AIDS Research   (Thailand)

^b Southeast Asia Research Collaboration with Hawaii (SEARCH)   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Antiretroviral therapy; Children; Drug resistance; HIV; Pediatric; Second line; Treatment failure

Indexed keywords

ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR;

BONE DENSITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LOW DRUG DOSE; NEPHROTOXICITY; NEUTROPENIA; PERINATAL INFECTION; PRACTICE GUIDELINE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS MUTATION;

EID: 70349378817     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.09.28     Document Type: Review

References (66)

1. Prasitsuebsai W, Bowen A, Pang J, Hesp C, Kariminia A, Sohn AH: Regional Survey of HIV Clinical Care Resources and Management Practices in the TREAT Asia Pediatric Program. Presented at: Australasian Society of Infectious Diseases Annual Scientific Conference. Sydney, Australia, 25-28 March 2009.
2. van Griensven J, De Naeyer L, Uwera J, Asiimwe A, Gazille C, Reid T: Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/ nurse-based care. BMC Pediatr. 8, 39 (2008).
3. Jaspan HB, Berrisford AE, Boulle AM: Two-year outcomes of children on nonnucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr. Infect. Dis. J. 27, 993-998 (2008). ■ Comparison of antiretroviral treatment (ART) outcomes between non-nucleoside reverse-transcriptase versus protease inhibitor (PI) regimens.
4. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A: Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 22, 1305-1312 (2008).
5. Adje-Toure C, Hanson DL, Talla-Nzussouo N et al.: Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res. Hum. Retroviruses 24, 911-917 (2008).
6. Zhang F, Haberer JE, Zhao Y et al.: Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year ana lysis of clinical, immunologic, and virologic outcomes. J. Acquir. Immune Defic. Syndr. 46, 594-598 (2007). ■ Compares treatment outcomes between those initiated on ART before a comprehensive national program and those who had access to adherence support.
7. Agwu A, Lindsey JC, Ferguson K et al.: Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS 22, 545-552 (2008).
8. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Pediatr. Infect. Dis. J. 12, 513-522 (1993).
9. Guidelines for the use of antiretroviral agents in pediatric HIV infection - HRSA. Request for comments. Fed. Regist. 62, 51115-51116 (1997).
10. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention. MMWR Recomm. Rep. 47, 1-43 (1998).
11. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 22, 1971-1977 (2008).
12. Moore DM, Awor A, Downing R et al.: CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 49, 477-484 (2008).
13. Reynolds SJ, Nakigozi G, Newel K et al.: Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 23, 697-700 (2009).
14. Kovacs A, Montepiedra G, Carey V et al.: Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J. Infect. Dis. 192, 296-302 (2005). (Pubitemid 40993399)
15. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L: HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 24, 1449-1454 (2008).
16. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S: HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J. Trop. Med. Public Health 40, 83-88 (2009).
17. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V: Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr. Infect. Dis. J. (2009) (Epub ahead of print). ■ One of the first published studies to examine predictors of failure together with resistance genotypes in a middle-income countries. Children largely treated with adult fixed-dose combinations.
18. Bunupuradah T, Aurpibul L, Ananworanich J, Puthanakit T: The effectiveness of highly active antiretroviral therapy among HIV-infected children in Asian countries. Asian Biomed. 3, 1-12 (2009).
19. Prasitsuebsai W, Bowen A, Pang J, Hesp C, Kariminia A, Sohn AH: Regional Survey of HIV Clinical Care Resources and Management Practices in the TREAT Asia Pediatric Program. Presented at: Australasian Society of Infectious Diseases Annual Scientific Conference. Sydney, Australia, 25-28 March 2009.
20. van Griensven J, De Naeyer L, Uwera J, Asiimwe A, Gazille C, Reid T: Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/ nurse-based care. BMC Pediatr. 8, 39 (2008).
21. Jaspan HB, Berrisford AE, Boulle AM: Two-year outcomes of children on nonnucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr. Infect. Dis. J. 27, 993-998 (2008). ■ Comparison of antiretroviral treatment (ART) outcomes between non-nucleoside reverse-transcriptase versus protease inhibitor (PI) regimens.
22. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A: Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 22, 1305-1312 (2008).
23. Adje-Toure C, Hanson DL, Talla-Nzussouo N et al.: Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res. Hum. Retroviruses 24, 911-917 (2008).
24. Zhang F, Haberer JE, Zhao Y et al.: Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year ana lysis of clinical, immunologic, and virologic outcomes. J. Acquir. Immune Defic. Syndr. 46, 594-598 (2007). ■ Compares treatment outcomes between those initiated on ART before a comprehensive national program and those who had access to adherence support.
25. Agwu A, Lindsey JC, Ferguson K et al.: Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS 22, 545-552 (2008).
26. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Pediatr. Infect. Dis. J. 12, 513-522 (1993).
27. Guidelines for the use of antiretroviral agents in pediatric HIV infection - HRSA. Request for comments. Fed. Regist. 62, 51115-51116 (1997).
28. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention. MMWR Recomm. Rep. 47, 1-43 (1998).
29. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 22, 1971-1977 (2008).
30. Moore DM, Awor A, Downing R et al.: CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 49, 477-484 (2008).
31. Reynolds SJ, Nakigozi G, Newel K et al.: Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 23, 697-700 (2009).
32. Kovacs A, Montepiedra G, Carey V et al.: Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J. Infect. Dis. 192, 296-302 (2005). (Pubitemid 40993399)
33. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L: HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 24, 1449-1454 (2008).
34. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S: HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J. Trop. Med. Public Health 40, 83-88 (2009).
35. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V: Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr. Infect. Dis. J. (2009) (Epub ahead of print). ■ One of the first published studies to examine predictors of failure together with resistance genotypes in a middle-income countries. Children largely treated with adult fixed-dose combinations.
36. Bunupuradah T, Aurpibul L, Ananworanich J, Puthanakit T: The effectiveness of highly active antiretroviral therapy among HIV-infected children in Asian countries. Asian Biomed. 3, 1-12 (2009).
37. Vigano A, Meroni L, Marchetti G et al.: Successful rescue therapy with a darunavir/ ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. Antivir. Ther. 13, 839-843 (2008).
38. Konigs C, Feiterna-Sperling C, Esposito S et al.: Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009 (Abstract 879).
39. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W: Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr. HIV Res. 6, 474-476 (2008).
40. Kekitinwa A, Friedman D, Coakley E, Lie Y, Graziano F: Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first line ART. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009 (Abstract 891).
41. Steigbigel RT, Cooper DA, Kumar PN et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359, 339-354 (2008).
42. Steigbigel RT, Cooper D, Eron JE et al.: 96-week results from BENCHMRK 1 and 2 Phase III studies of raltegravir in patients failing ART with triple class resistant HIV. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009 (Abstract 571b).
43. Thuret I, Tamalet C, Reliquet V et al.: Raltegravir in children and adolescents: The French Expanded Access Program. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009 (Abstract 873).
44. Wiznia A, Samson P, Acosta E et al.: Safety and efficacy of raltegravir in pediatric HIV infection: preliminary ana lysis from the international maternal pediatric adolescent AIDS clinical trial group, P1066. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009 (Abstract 874).
45. Gulick RM, Lalezari J, Goodrich J et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008).
46. Reynes J, Arasteh K, Clotet B et al.: TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 21, 533-543 (2007).
47. Bellibas SE, Siddique Z, Dorr A et al.: Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr. Infect. Dis. J. 23, 1137-1141 (2004).
48. Feiterna-Sperling C, Walter H, Wahn V, Kleinkauf N: A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide. Eur. J. Med. Res. 14, 44-46 (2009).
49. Violari A, Cotton MF, Gibb DM et al.: Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359, 2233-2244 (2008).
50. WHO, Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting WHO Headquarters, Geneva, Switzerland, 10-11 April 2008.
51. Sohn AH, Ananworanich J: How can we simplify antiretroviral therapy in children? Curr. Opin. HIV AIDS 2, 426-430 (2007).
52. O'Brien DP, Sauvageot D, Zachariah R, Humblet P: In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 20, 1955-1960 (2006).
53. UNAIDS, Report on the global HIV/AIDS epidemic 2008. www.unaids.org.
54. UNICEF, Children and AIDS: Third Stocktaking Report, 2008. 2009, UNICEF: Geneva, Switzerland. www.unicef.org
55. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. www.aidsinfo.nih.gov ■■ Provides information on rationale and guidance for when and how to switch antiretrovirals when treatment fails, and on using novel drugs in children.
56. Paediatric European Network for Treatment of AIDS (PENTA): PENTA guidelines for the use of antiretroviral therapy in paediatric infection - 2008 draft revision (2008). www.pentatrials.org
57. PENTA. www.pentatrials.org/trials.htm#penpact1
58. WHO, Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public-health approach (2006). www.who.int
59. Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy. http://clinicaltrials.gov/ct2/show/ NCT00352 053?term=NCT00352053&rank=1
60. Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children (Ages 2- 〈12). http:// clinicaltrials.gov/ct2/show/NCT0052 8957?term=NCT00528957&rank=1
61. A Pediatric Trial to Provide Dose Recommendation of TMC114/Rtv in HIV-1 Infected Children and Adolescents. http://clinicaltrials.gov/ct2/show/NCT00355 524?term=NCT00355524&rank=1
62. TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents. http://clinicaltrials.gov/ct2/show/NCT00665 847?term=NCT00665847&rank=1
63. Safety and Effectiveness of Raltegravir (MK-0518) in Treatment- Experienced, HIV-Infected Children and Adolescents. http://clinicaltrials.gov/ ct2/show/NCT00485 264?term=NCT00485264&rank=1
64. An Open Label Pharmacokinetic, Safety and Efficacy Study of Maraviroc in Combination With Background Therapy for the Treatment of HIV-1 Infected, CCR5-Tropic Child. http://clinicaltrials.gov/ct2/show/NCT0079 1700?term=NCT00791700&rank=1
65. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. Department of Health and Human Services. 3 November, 1-139 (2008). www.aidsinfo.nih.gov
66. WHO: List of prequalified medicinal products. www.who.int/prequal/query/ ProductRegistry. aspx?list=ha